Instrument Inactif

Communiqués Stayble Therapeutics AB

Actions

STABL

SE0013513652

Recherche biotechnologique et médicale

Communiqués

14/01/25	Interview with US payer expert on the US market and STA363's potential	AQ
02/01/25	Interview with Jane Buus Laursen - an experienced pharma dealmaker and Board member of Stayble	AQ
11/12/24	Stayble Therapeutics reports additional data strengthening the STA363 treatment for pain caused by disc herniation	AQ
13/11/24	Stayble Therapeutics' STA363 receives positive phase 1b results	AQ
12/01/24	Stayble's CEO to BioStock: "We are looking forward to new study results in 2024"	AQ
18/12/23	BioStock: Stayble's new analyses of phase IIb study strengthen disc herniation project	AQ
22/11/23	BioStock: Stayble Therapeutics shifts focus to phase Ib study in disc herniation	AQ
09/11/23	BioStock: Stayble did not reach the primary endpoint in phase IIb	AQ
03/11/23	BioStock: Stayble Therapeutics presents phase IIb data within one month	AQ
14/09/23	BioStock: Stayble reports last patient last visit in the phase IIb study	AQ
04/09/23	BioStock: Stayble enrols the first patient in herniated disc study	AQ
25/08/23	BioStock: Progress for Stayble Therapeutics in the second quarter	AQ
24/07/23	BioStock: Stayble's phase IIb study nears the finishing line	AQ
20/06/23	BioStock: Stayble Therapeutics looks towards its most important year so far	AQ
27/04/23	BioStock: Newly appointed CMO sees potential in Stayble Therapeutics	AQ
18/04/23	BioStock: Stayble presents additional positive interim data	AQ
07/03/23	BioStock: Stayble adds disc herniation to the pipeline - study approved	AQ
15/02/23	BioStock: Stayble is done with the 6-month follow-up	AQ
27/01/23	BioStock: Stayble approaches study results and other milestones	AQ
15/12/22	BioStock: Great interest at conferences for Stayble's treatment	AQ
04/10/22	BioStock at NLSDays: Stayble steps up partnering activities	AQ
05/09/22	BioStock: Stayble reaches important milestone - patient recruitment completed	AQ
24/08/22	BioStock: Stayble sums up and looks ahead	AQ
18/07/22	BioStock: Stayble's pathway to phase III and market	AQ
29/06/22	BioStock: 10 advantages of Stayble's treatment	AQ